TABLE 4.
Comparison of in vitro antifungal susceptibility of C. bracarensis with those of C. glabrata, C. nivariensis, and N. delphensis
| Organism | MIC (μg/ml)
|
||||||
|---|---|---|---|---|---|---|---|
| FLC | ITC | PSCa | VRC | CASP | 5FC | AMB | |
| C. glabrata (control) | 16 | 0.5 | 1 | 0.25 | 0.12 | 0.03 | 0.064 |
| C. bracarensis (HOP-15) | 16 | 0.5 | 0.5 | 0.25 | 0.12 | 0.03 | 0.032 |
| C. bracarensis (TS) | 8 | 0.5 | 0.5 | 0.12 | 0.25 | 0.03 | 0.023 |
| C. nivariensis (TS) | 16 | 2 | 2 | 0.25 | 0.25 | 0.5 | 0.5 |
| N. delphensis (TS) | 128 | >16 | 8 | 4 | 0.25 | 0.25 | 0.032 |
| Cagl-78 | 8 | 0.25 | 0.5 | 0.06 | 0.25 | 0.12 | 1 |
| Cagl-112 | 4 | 0.25 | 0.25 | 0.06 | 0.25 | 0.12 | 0.094 |
| Cagl-121 | 256 | >16 | >8 | 8 | 0.12 | 0.25 | 0.19 |
a
PSC, posaconazole.